| scholarly article | Q13442814 |
| P50 | author | Theodore J. Brown | Q46857872 |
| Neil J. MacLusky | Q54088209 | ||
| P2093 | author name string | D J Drucker | |
| P L Brubaker | |||
| A L Joyner | |||
| L A Scrocchi | |||
| A B Auerbach | |||
| P2860 | cites work | The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones | Q58169355 |
| Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man | Q58449161 | ||
| Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y | Q59055743 | ||
| Estrous cyclicity of 125I-cholecystokinin octapeptide binding in the ventromedial hypothalamic nucleus. Evidence for downmodulation by estrogen | Q69000557 | ||
| Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung | Q69844332 | ||
| Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle | Q72572861 | ||
| Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor | Q24309772 | ||
| A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 | ||
| Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor | Q24318252 | ||
| Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 | Q24563957 | ||
| Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line | Q24609542 | ||
| Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences | Q28306665 | ||
| Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene | Q28512170 | ||
| Derivation of completely cell culture-derived mice from early-passage embryonic stem cells | Q29547491 | ||
| Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal | Q34147299 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons | Q37351161 | ||
| New developments in the incretin concept | Q39832287 | ||
| Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas | Q40920945 | ||
| Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I | Q41672615 | ||
| Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. | Q42492827 | ||
| Glucagon-like peptide-1 7-36: a physiological incretin in man. | Q43623564 | ||
| Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus | Q45306841 | ||
| Endogenous corticotropin-releasing factor modulates feeding induced by neuropeptide Y or a tail-pinch stressor | Q48435313 | ||
| Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase | Q48591402 | ||
| Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| glucose intolerance | Q2661464 | ||
| satiety | Q1562684 | ||
| P304 | page(s) | 1254-1258 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | ??? | Q1633234 |
| P1476 | title | Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene | |
| P478 | volume | 2 |
| Q37568754 | A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease |
| Q43756107 | A new glucagon and GLP-1 co-agonist eliminates obesity in rodents |
| Q44297979 | A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. |
| Q35138670 | A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor |
| Q41821895 | Ability of GLP-1 to decrease food intake is dependent on nutritional status |
| Q53161614 | Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. |
| Q38344593 | Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man. |
| Q35175696 | Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency |
| Q58447525 | Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow |
| Q48183718 | Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice |
| Q36758533 | Alterations in energy balance following exenatide administration |
| Q58448944 | Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans |
| Q49952246 | Animal models of obesity and diabetes mellitus |
| Q33338102 | Anorectic brainstem peptides: more pieces to the puzzle |
| Q36807579 | Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake |
| Q51278212 | Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment. |
| Q37662974 | Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice |
| Q40860075 | Behavior in mice with targeted disruption of single genes |
| Q39932172 | Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models. |
| Q44807616 | Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats. |
| Q36575421 | Biologic actions and therapeutic potential of the proglucagon-derived peptides |
| Q64218606 | Blocking Glucagon Like Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity for Beta Cells in a Mouse Model of Type 1 Diabetes |
| Q47172962 | Body weight homeostat that regulates fat mass independently of leptin in rats and mice |
| Q44495085 | Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects |
| Q35991683 | Brain GLP-1 and insulin sensitivity |
| Q36484283 | Cardiovascular biology of the incretin system |
| Q39146023 | Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides |
| Q51041822 | Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats |
| Q34132510 | Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival |
| Q89580555 | Continuous glucose monitoring reveals glycemic variability and hypoglycemia after vertical sleeve gastrectomy in rats |
| Q35929005 | Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice |
| Q28510313 | Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion |
| Q37451266 | Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. |
| Q46753570 | Deletion of peptide amidation enzymatic activity leads to edema and embryonic lethality in the mouse |
| Q33661003 | Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine. |
| Q47366967 | Development and characterisation of a novel glucagon like peptide-1 receptor antibody |
| Q36253123 | Development of the endocrine pancreas |
| Q37326969 | Developmental biology of the pancreas: a comprehensive review |
| Q42837261 | Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. |
| Q36339639 | Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling |
| Q38066566 | Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. |
| Q47333882 | Discovery, characterization, and clinical development of the glucagon-like peptides |
| Q37558852 | Disruption of Glucagon-Like Peptide 1 Signaling in Sim1 Neurons Reduces Physiological and Behavioral Reactivity to Acute and Chronic Stress. |
| Q34074250 | Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects |
| Q87587380 | Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength |
| Q43253089 | DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes |
| Q42136958 | Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis |
| Q38270358 | Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency |
| Q43651347 | Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1. |
| Q38088108 | Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. |
| Q34620465 | Emerging role of GLP-1 receptor agonists in the treatment of obesity |
| Q35809679 | Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. |
| Q35545683 | Enhancing Incretin Action for the Treatment of Type 2 Diabetes |
| Q37662980 | Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport |
| Q40889860 | Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders |
| Q36877205 | Evolution of exenatide as a diabetes therapeutic |
| Q43638669 | Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers |
| Q36838681 | Expression of the GLP-1 receptor in mouse, rat, and human pancreas |
| Q30478488 | Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure |
| Q44665356 | Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system |
| Q33544987 | Feeding and body-weight regulation by hypothalamic neuropeptides--mediation of the actions of leptin |
| Q35001607 | Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice |
| Q26828589 | From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior |
| Q28511968 | G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction |
| Q38223619 | G protein-coupled receptors in energy homeostasis |
| Q90051591 | GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats |
| Q33609502 | GIP and GLP-1, the two incretin hormones: Similarities and differences |
| Q39473017 | GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. |
| Q58448618 | GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine |
| Q37885717 | GLP-1 and energy balance: an integrated model of short-term and long-term control |
| Q35200252 | GLP-1 based therapeutics: simultaneously combating T2DM and obesity. |
| Q34336097 | GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure |
| Q35098054 | GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. |
| Q37629291 | GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents |
| Q49414493 | GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose |
| Q33734024 | GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly? |
| Q27000749 | GLP-1, the gut-brain, and brain-periphery axes |
| Q26997149 | GLP-1-based strategies: a physiological analysis of differential mode of action |
| Q41490586 | GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor |
| Q55116155 | GLP-1: target for a new class of antidiabetic agents? |
| Q36153247 | GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities |
| Q48325811 | Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons |
| Q34758871 | Gastric inhibitory polypeptide: the neglected incretin revisited |
| Q28209374 | Gastric leptin: a putative role in the short-term regulation of food intake |
| Q35762305 | Gastro-intestinal hormones GIP and GLP-1. |
| Q38208929 | Gastrointestinal hormones and polycystic ovary syndrome |
| Q43288793 | Gastrointestinal hormones in food intake control |
| Q24669951 | Gastrointestinal hormones regulating appetite |
| Q35251043 | Gastrointestinal regulation of food intake |
| Q47178961 | Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain |
| Q38048602 | Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis |
| Q48926149 | Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor. |
| Q37246805 | Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling |
| Q28067465 | Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes |
| Q58448872 | Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential |
| Q28581928 | Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling |
| Q35772023 | Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells |
| Q34635520 | Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives |
| Q45061870 | Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. |
| Q28084873 | Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling |
| Q37377728 | Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans |
| Q42176081 | Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons |
| Q34401791 | Glucagon-like peptide 1(GLP-1) in biology and pathology |
| Q41982493 | Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice |
| Q35772029 | Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes |
| Q28376612 | Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis |
| Q77439091 | Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes |
| Q42490547 | Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes |
| Q46278128 | Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication |
| Q27319066 | Glucagon-like peptide-1 is specifically involved in sweet taste transmission. |
| Q38328379 | Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice |
| Q28202403 | Glucagon-like peptide-1 receptor is involved in learning and neuroprotection |
| Q36422653 | Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. |
| Q34157515 | Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance |
| Q33434017 | Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. |
| Q40657491 | Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. |
| Q35565562 | Glucagon-like peptide-1: a potent regulator of food intake in humans |
| Q36056970 | Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors |
| Q77743538 | Glucose action 'beyond ionic events' in the pancreatic beta cell |
| Q28510783 | Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice |
| Q48586968 | Glucose metabolism is altered after loss of L cells and α-cells but not influenced by loss of K cells |
| Q37403983 | Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). |
| Q33603384 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas |
| Q44286265 | Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. |
| Q45034178 | Grape powder attenuates the negative effects of GLP-1 receptor antagonism by exendin-3 (9-39) in a normoglycemic mouse model |
| Q34060758 | Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. |
| Q36452530 | Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism |
| Q36455914 | Gut peptides and the regulation of appetite. |
| Q31157033 | Gut peptides and type 2 diabetes mellitus treatment |
| Q53425804 | How and why do gastrointestinal peptides influence food intake? |
| Q34143823 | How obesity develops: insights from the new biology |
| Q51545833 | Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression. |
| Q35625609 | Hyperinsulinism in infancy: from basic science to clinical disease. |
| Q36979291 | Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. |
| Q44601453 | Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene |
| Q37892968 | Hypothalamic control of energy and glucose metabolism |
| Q37669693 | Hypothalamic lipids and the regulation of energy homeostasis. |
| Q77909734 | Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose |
| Q34519292 | Impaired enteroendocrine development in intestinal-specific Islet1 mouse mutants causes impaired glucose homeostasis |
| Q44848282 | Importance of orexigenic counter-regulation for multiple targeted feeding inhibition |
| Q28574165 | Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats |
| Q24298172 | In vitro expression of NGN3 identifies RAB3B as the predominant Ras-associated GTP-binding protein 3 family member in human islets |
| Q42736812 | Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection |
| Q34374336 | Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors |
| Q35131698 | Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation |
| Q26744254 | Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? |
| Q33753169 | Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy |
| Q37316259 | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. |
| Q34512348 | Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. |
| Q35669308 | Incretins, insulin secretion and Type 2 diabetes mellitus |
| Q38225693 | Incretins: their physiology and application in the treatment of diabetes mellitus. |
| Q35621637 | Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor |
| Q87350483 | Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression |
| Q33569425 | Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell |
| Q36740460 | Insulin-like peptide 5 is a microbially regulated peptide that promotes hepatic glucose production |
| Q50942135 | Intestinal growth-promoting properties of glucagon-like peptide-2 in mice |
| Q26749196 | Is GLP-1 a hormone: Whether and When? |
| Q33803409 | Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? |
| Q34232252 | KO's and organisation of peptidergic feeding behavior mechanisms |
| Q89636178 | L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling |
| Q89935832 | Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight |
| Q38342036 | Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents |
| Q90390319 | Leptin receptor-expressing nucleus tractus solitarius neurons suppress food intake independently of GLP1 in mice |
| Q36302704 | Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity |
| Q88732200 | Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons |
| Q46099197 | Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor |
| Q33815664 | Loss of enteroendocrine cells in mice alters lipid absorption and glucose homeostasis and impairs postnatal survival |
| Q28651068 | Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility |
| Q92540070 | MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin |
| Q24683764 | Mechanisms of action of glucagon-like peptide 1 in the pancreas |
| Q35762303 | Mechanisms of glucose sensing and multiplicity of glucose sensors |
| Q37913526 | Metabolic impact of glucagon deficiency |
| Q33642038 | Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells |
| Q35144434 | Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance |
| Q90213470 | Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance |
| Q38974881 | Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology |
| Q37070399 | Modulation of taste sensitivity by GLP-1 signaling |
| Q37635255 | Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. |
| Q34420612 | Mouse feeding behavior: ethology, regulatory mechanisms and utility for mutant phenotyping |
| Q38088734 | Mouse genetics in drug target discovery and validation: no simple answers to complex problems |
| Q36312680 | Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice |
| Q30412673 | Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect |
| Q43635126 | Neuropeptide regulation of feeding in catfish, Ictalurus punctatus: a role for glucagon-like peptide-1 (GLP-1)? |
| Q35048780 | Neuropeptides, food intake and body weight regulation: a hypothalamic focus |
| Q34014393 | New approaches in the treatment of type 2 diabetes |
| Q51862698 | New gene targets for glucagon-like peptide-1 during embryonic development and in undifferentiated pluripotent cells. |
| Q35037275 | New pharmacological tools for obesity |
| Q42078124 | New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins |
| Q36455865 | Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations |
| Q28475510 | Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist |
| Q26749181 | Novel extrapancreatic effects of incretin |
| Q40717418 | Novel insulin/GIP co-producing cell lines provide unexpected insights into Gut K-cell function in vivo |
| Q37852801 | Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential |
| Q36507088 | Obesity and the role of gut and adipose hormones in female reproduction |
| Q34743295 | Obesity therapy: altering the energy intake-and-expenditure balance sheet |
| Q33864496 | Of mice and MEN: what transgenic models tell us about hypothalamic control of energy balance |
| Q54106557 | On the treatment of diabetes mellitus with glucagon-like peptide-1. |
| Q42712582 | On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. |
| Q90709770 | Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism |
| Q41104121 | Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness |
| Q40512418 | Oxyntomodulin regulates resetting of the liver circadian clock by food. |
| Q35640531 | Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. |
| Q26766485 | Pancreatic regulation of glucose homeostasis |
| Q39966431 | Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells |
| Q36728791 | Peptide regulators of peripheral taste function |
| Q47873900 | Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats |
| Q35204654 | Peripheral mechanisms in appetite regulation |
| Q36753785 | Peripheral tissue-brain interactions in the regulation of food intake |
| Q27027920 | Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease |
| Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
| Q74616099 | Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition |
| Q38024321 | Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus |
| Q37306261 | Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats |
| Q34977231 | Preclinical developments in type 2 diabetes |
| Q34452524 | Proglucagon-derived peptides: mechanisms of action and therapeutic potential |
| Q36797390 | Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathway |
| Q43244961 | Protection from high-fat-diet-induced impaired glucose tolerance in female Sprague-Dawley rats |
| Q36756501 | Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis |
| Q53601992 | Quantitative trait loci for carbohydrate and total energy intake on mouse chromosome 17: congenic strain confirmation and candidate gene analyses (Glo1, Glp1r). |
| Q38077226 | Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. |
| Q42511192 | Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor |
| Q93174230 | Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery |
| Q57591254 | Role of GIP receptor signaling in β-cell survival |
| Q33812543 | Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress |
| Q51316102 | Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients. |
| Q37708356 | Role of the glucagon-like-peptide-1 receptor in the control of energy balance |
| Q89230553 | Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates |
| Q42737933 | Satiation and stress-induced hypophagia: examining the role of hindbrain neurons expressing prolactin-releasing Peptide or glucagon-like Peptide 1. |
| Q36821806 | Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior |
| Q52807797 | Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling. |
| Q48094071 | Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY. |
| Q52709053 | Structure and Function of Bone Marrow Adipocytes. |
| Q40658362 | Studies with GIP/Ins cells indicate secretion by gut K cells is KATP channel independent |
| Q92932298 | Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics |
| Q36524107 | Supplementation with a fish protein hydrolysate (Micromesistius poutassou): effects on body weight, body composition, and CCK/GLP-1 secretion |
| Q42492321 | Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice |
| Q35951285 | T1R and T2R receptors: the modulation of incretin hormones and potential targets for the treatment of type 2 diabetes mellitus. |
| Q53257766 | TCF1 links GIPR signaling to the control of beta cell function and survival. |
| Q37091579 | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins |
| Q64118590 | The Discovery and Development of Liraglutide and Semaglutide |
| Q51091690 | The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice |
| Q36297531 | The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. |
| Q30596646 | The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss |
| Q36135121 | The brain-adipose axis: a review of involvement of molecules |
| Q33835949 | The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight |
| Q58448710 | The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity |
| Q41038731 | The endogenous preproglucagon system is not essential for gut growth homeostasis in mice |
| Q30365939 | The entero-insular axis: implications for human metabolism. |
| Q42255930 | The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. |
| Q37125933 | The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action |
| Q35181801 | The glucagon-like peptides: a double-edged therapeutic sword? |
| Q36187070 | The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management |
| Q36902183 | The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q28273497 | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes |
| Q36118673 | The incretins: a link between nutrients and well-being |
| Q80282718 | The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin |
| Q38088195 | The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists |
| Q36174532 | The role of apolipoprotein A-IV in regulating glucagon-like peptide-1 secretion |
| Q35251016 | The role of gut hormones in glucose homeostasis |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q34648201 | Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes |
| Q35018510 | Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. |
| Q58433907 | Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression1This work was supported by a grant from the Crohn's and Colitis Foundation of America.1 |
| Q57292162 | Translating biased signaling in the ghrelin receptor system into differential in vivo functions |
| Q39501242 | Transplantation of PC1/3-Expressing alpha-cells improves glucose handling and cold tolerance in leptin-resistant mice |
| Q58448867 | Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1 |
| Q27863774 | Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1. |
| Q38006504 | Update on incretin hormones |
| Q36269671 | Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches |
| Q37015063 | Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency |
| Q37811421 | Wnt and Incretin Connections |
| Q74316848 | [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1] |
| Q35680897 | β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity |
Search more.